Ammar Kheder, MD
Epilepsy · Grand Rapids, MINPI 1770925976
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (42.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. DIXI Medical USA Corp accounts for 76.3% of it on its own, with 7 other manufacturers making up the rest. Among epilepsy clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 22 payments — averaging $546.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- DIXI Medical USA Corp$9K
- Aucta Pharmaceuticals, Inc.$3K
- Eisai Inc.$96
- Neurelis, Inc.$90
- SK Life Science, Inc.$64
- Catalyst Pharmaceuticals, Inc.$52
- plus $49 from 2 others
Across 6 payments — averaging $1874.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$11K
What the payments were for
- Consulting fees$2,50021%
- Travel & lodging$5,09942%
- Food & beverage$4,41737%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| DIXI Medical USA Corp | 15 | $9,166 |
| Aucta Pharmaceuticals, Inc. | 1 | $2,500 |
| Eisai Inc. | 1 | $96 |
| Neurelis, Inc. | 1 | $90 |
| SK Life Science, Inc. | 1 | $64 |
| Catalyst Pharmaceuticals, Inc. | 1 | $52 |
| UCB, Inc. | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Motpoly XR$2,500
How this compares
$12,016 in reported general payments places this provider in the 90th percentile of 30 epilepsy providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 12 | $1,783 |
| Lacosamide | 18 | $1,070 |
| Levetiracetam | 19 | $789 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Grand Rapids
- David BurdetteGrand Rapids$1.4M
- Evan TankGrand Rapids$28K
- Charles AsburyGrand Rapids$2K
- Rachel FabrisGrand Rapids$2K
- David OrtizGrand Rapids$2K
- Philip McCarthyGrand Rapids$1K
- Luke SalbertGrand Rapids$962
- Desiree MarkantoneGrand Rapids$431
- Shan AbbasGrand Rapids$298
- Erin OkazakiGrand Rapids$260
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.